Success Metrics

Clinical Success Rate
85.0%

Based on 17 completed trials

Completion Rate
85%(17/20)
Active Trials
2(8%)
Results Posted
53%(9 trials)
Terminated
3(13%)

Phase Distribution

Ph phase_4
1
4%
Ph phase_3
2
8%
Ph phase_1
7
29%
Ph phase_2
11
46%
Ph not_applicable
2
8%

Phase Distribution

7

Early Stage

11

Mid Stage

3

Late Stage

Phase Distribution23 total trials
Phase 1Safety & dosage
7(30.4%)
Phase 2Efficacy & side effects
11(47.8%)
Phase 3Large-scale testing
2(8.7%)
Phase 4Post-market surveillance
1(4.3%)
N/ANon-phased studies
2(8.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.0%

17 of 20 finished

Non-Completion Rate

15.0%

3 ended early

Currently Active

2

trials recruiting

Total Trials

24

all time

Status Distribution
Active(2)
Completed(17)
Terminated(3)
Other(2)

Detailed Status

Completed17
Terminated3
unknown2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
24
Active
2
Success Rate
85.0%
Most Advanced
Phase 4

Trials by Phase

Phase 17 (30.4%)
Phase 211 (47.8%)
Phase 32 (8.7%)
Phase 41 (4.3%)
N/A2 (8.7%)

Trials by Status

unknown28%
terminated313%
recruiting28%
completed1771%

Recent Activity

Clinical Trials (24)

Showing 20 of 24 trialsScroll for more
NCT03670966Phase 1

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Recruiting
NCT06752694Phase 2

Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia

Recruiting
NCT03626285

Bone Marrow Transplantation Using CD34-Selected Stem Cells From Related or Unrelated Donors in Treating Participants With Cancer or Other Disorders

Unknown
NCT00534469Phase 2

Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R

Completed
NCT02446964Phase 1

Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia

Completed
NCT01578109Phase 1

Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia

Completed
NCT02995330Phase 1

Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer

Terminated
NCT00630565Phase 2

Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia

Terminated
NCT01904136Phase 1

Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

Completed
NCT01850108Not Applicable

Non-Myeloablative Conditioning and Bone Marrow Transplantation

Unknown
NCT00352976Phase 2

TBI Dose De-escalation for Fanconi Anemia

Completed
NCT00957931Phase 2

Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs

Completed
NCT00622895Phase 1

Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis

Completed
NCT00004474Phase 3

Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia

Completed
NCT00801632Phase 2

Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection

Completed
NCT00066417Phase 2

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

Terminated
NCT00002829Phase 2

Bone Marrow Transplantation in Treating Patients With Lymphoma

Completed
NCT00003146Phase 2

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Completed
NCT01015261Phase 2

Allogenic Bone Marrow Transplantation (BMT) Compare With Cytoreduction and Chemotherapy in Acute Lymphoblastic Leukemia (ALL) Patients

Completed
NCT01020175Phase 3

Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation

Completed

Drug Details

Intervention Type
PROCEDURE
Total Trials
24